Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells

作者：Allison Thomas F; Andrews Peter W; Avior Yishai; Barbaric Ivana; Benvenisty Nissim; Bock Christoph; Brehm Jennifer; Bruestle Oliver; Damjanov Ivan; Elefanty Andrew; Felkner Daniel; Gokhale Paul J; Halbritter Florian; Healy Lyn E; Hu Tim X; Knowles Barbara B; Loring Jeanne F; Ludwig Tenneille E; Mayberry Robyn; Micallef Suzanne; Mohamed Jameelah S; Mueller Franz Josef; Mummery Christine L; Nakatsuji Norio; Ng Elizabeth S; Oh Steve K W; O'Shea Orla

来源：Nature Communications, 2018, 9(1): 1925.

DOI：10.1038/s41467-018-04011-3

The International Stem Cell Initiative compared several commonly used approaches to assess human pluripotent stem cells (PSC). PluriTest predicts pluripotency through bioinformatic analysis of the transcriptomes of undifferentiated cells, whereas, embryoid body (EB) formation in vitro and teratoma formation in vivo provide direct tests of differentiation. Here we report that EB assays, analyzed after differentiation under neutral conditions and under conditions promoting differentiation to ectoderm, mesoderm, or endoderm lineages, are sufficient to assess the differentiation potential of PSCs. However, teratoma analysis by histologic examination and by TeratoScore, which estimates differential gene expression in each tumor, not only measures differentiation but also allows insight into a PSC's malignant potential. Each of the assays can be used to predict pluripotent differentiation potential but, at this stage of assay development, only the teratoma assay provides an assessment of pluripotency and malignant potential, which are both relevant to the pre-clinical safety assessment of PSCs.

• 出版日期2018-5-15